Hemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito B

dc.creatorConte L,Guillermo
dc.creatorFigueroa M,Gastón
dc.creatorAravena R,Paola
dc.creatorGonzáles G,Néstor
dc.creatorAraos H,Daniel
dc.creatorCuneo V,Marianela
dc.date2011-03-01
dc.date.accessioned2017-03-07T16:37:59Z
dc.date.available2017-03-07T16:37:59Z
dc.identifierhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000300012
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/404934
dc.descriptionWe report a 54-year-old male presenting with a history or recurrent nose bleeds and ecchymoses. The coagulation study showed a prolongedpartial thromboplastin time, a factor VIII of 8% and a high inhibitor titer (193 Bethesda units). A diagnosis of acquired hemophilia A was reached. The patient was initially treated with cyclophosphamide for seven months without response. Therefore rituximab in doses of 375 mglm²Iweek for four weeks was started. After starting treatment, the patient had a hematoma in the psoas muscle with a concomitantfactor VIII ofless than 5%, thatwas treated with local measures. Thereafter, aprogressive reduction in inhibitor titers was observed, until its disappearance atfive months of treatment. Factor VIII levéis normalized and the patient has not experienced abnormal bleeding episodes. The patient remains in remission after 67 months offollow up. Rituximab, a chimeric monoclonal antibody against theprotein CD 20 is an effective treatment in acquired hemophilia A.
dc.formattext/html
dc.languagees
dc.publisherSociedad Médica de Santiago
dc.sourceRevista médica de Chile v.139 n.3 2011
dc.subjectAntibodies
dc.subjectmonoclonal
dc.subjectFactor VIII
dc.subjectHemophilia A
dc.subjectRituximab
dc.titleHemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito B
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución